Intel stock extends gains after report of possible U.S. government stake
Investing.com - H.C. Wainwright raised its price target on Genmab A/S (NASDAQ:GMAB) to $36.00 from $35.00 on Friday, while maintaining a Buy rating on the stock. The company, currently trading at $22.98, shows impressive financial health with a 94.54% gross profit margin and a favorable P/E ratio of 9.99.
The price target increase follows the firm’s assessment of upcoming catalysts for the Danish biotechnology company, including a Phase 2 data update for acasunlimab in second-line or later non-small cell lung cancer expected later in 2025. According to InvestingPro data, Genmab demonstrates strong financial fundamentals with impressive revenue growth of 33% over the last twelve months, positioning it well for these developments.
H.C. Wainwright also highlighted an anticipated update regarding next steps for GEN1042 in 2025 as another key catalyst for the company.
The research firm noted a potential FDA approval by November 30, 2025, for the combination of epcoritamab with rituximab and lenalidomide for treating adult patients with relapsed or refractory follicular lymphoma who have received at least one prior systemic therapy.
According to H.C. Wainwright, the submission for this potential approval was based on statistically significant improvements in overall response rate (95.7%, P
In other recent news, Genmab A/S has reported its financial results for the second quarter of 2025, showcasing a strong performance that exceeded market expectations. The company achieved an earnings per share (EPS) of $0.542, which is a notable 39.4% increase over the anticipated $0.3888. Additionally, Genmab’s revenue reached $925 million, surpassing forecasts by 3.54%. In another development, Genmab announced a minor increase in its share capital by 0.01% through the exercise of employee warrants, adding 4,563 shares. These new shares are being subscribed in cash at varying prices, including DKK 1,025.00 for 2,580 shares, DKK 1,050.00 for 1,874 shares, and DKK 1,161.00 for 109 shares. The capital increase will occur without preemption rights for existing shareholders. These recent developments highlight Genmab’s financial strength and strategic moves in the market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.